Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis
NCT01065727
·
clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
250
Enrollment
OTHER
Sponsor class
Conditions
Multiple Sclerosis
Interventions
OTHER:
mitoxantrone - immunomodulator
OTHER:
natalizumab
Sponsor
Rennes University Hospital